Novo Nordisk could drop blood drug candidate-exec

Novo Nordisk could drop blood drug candidate-exec
COPENHAGEN (Reuters) - Denmark's Novo Nordisk could be a few months away from dropping a drug expected to replace crucial blood treatment Novoseven and seen as a potential blockbuster, the company said on Friday. The world's biggest insulin producer said it could be forced to drop haemophilia drug candidate, vatreptacoq alfa, unless phase III data proved very favorable. Drugs are classed as blockbusters if they reach annual sales above $1 billion within five years of launch. ...
Source: news.yahoo.com